ecancer

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA

9 Jun 2021

Radiation and immunology – a new therapeutic partnership

Dr Ralph Weichselbaum - University of Chicago, Chicago, USA

6 Jul 2015

Initial nivolumab-based treatment halts melanoma progression

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

1 Jun 2015

Phase III study finds initial nivolumab-based treatment halts melanoma progression

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

31 May 2015

Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

3 Jun 2013

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

3 Jun 2013

Ipilimumab and BRAF inhibitors for advanced melanoma

Dr Lynn Schuchter - University of Pennsylvania, USA

2 Jun 2013

Nivolumab produces long-lasting responses in patients with stage IV melanoma

Dr Mario Sznol - Yale Cancer Center, New Haven, USA

1 Jun 2013

Immunotherapy treatment for melanoma

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

21 Oct 2011

Ipilimumab improves survival in metastatic melanoma

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

17 Jun 2011

More from ecancer